Login
$CLYM
$9.82 -$0.12 (1.23%) After hours

$CLYM SEC Filings

Filed On Filing
09 Nov 2026 SCHEDULE 13D/A
05 Nov 2026 SCHEDULE 13G/A
05 Nov 2026 S-3ASR
05 Nov 2026 10-Q
05 Nov 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

CLYM116 Phase 1 data in healthy volunteers showed sustained >90% free APRIL suppression and ~70% Gd-IgA1 reduction at 12 weeks after a single dose, supporting every-12-week dosing

28 Oct 2026 SCHEDULE 13G
27 Oct 2026 SCHEDULE 13G
26 Oct 2026 8-K: Regulation FD Disclosure; Other Events

Forward Looking Statements This presentation contains “forward-looking statements” including, without limitation, statements regarding: future expectations, plans and prospects for Climb Bio; expectations regarding the therapeutic benefi...

23 Oct 2026 8-K: Regulation FD Disclosure; Other Events

Climb Bio and Mabworks Announce CLYM116/MIL116 Data Demonstrating Deep, Durable APRIL Suppression and ~70% Gd-IgA1 Reduction at ASN Kidney Week 2026

30 Sep 2026 Form 4: Ra Capital MANAGEMENT, L.p., Director and 6 others

Received 70,000 shares by exercise or conversion ($195K)

17 Sep 2026 Form 4: Thomas Stephen Basil, Director

Sold 100,000 shares ($1.37M)

15 Sep 2026 144
03 Sep 2026 8-K: Regulation FD Disclosure

R&D Spotlight: CLYM116 Initial Phase 1 Results September 3, 2026 Exhibit 99.2

14 Aug 2026 SCHEDULE 13G/A
14 Aug 2026 8-K: Other Events

On August 13, 2026, Beijing Mabworks Biotech Co., Ltd. announced the dosing of the first patient with immunoglobulin A nephropathy in a Phase 2 clinical trial in China, which is being conducted in collaboration with Climb Bio, Inc.

06 Aug 2026 10-Q
06 Aug 2026 8-K: Results of Operations and Financial Condition

CLYM116 Phase 1 data in healthy volunteers to be presented at R&D Spotlight Event on September 3, 2026

08 Jul 2026 SCHEDULE 13G
07 Jul 2026 SCHEDULE 13D/A
01 Jul 2026 Form 4: Ra Capital MANAGEMENT, L.p., Director and 6 others

Granted 70,284 Stock Option (Right to Buy)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support